drugset / Trial / NCT01035411

AZD9668 Relative Bioavailability

NCT01035411

Phase 1 Completed 15 enrolled AstraZeneca
RandomizedSingle-groupOpen-label

Summary

This clinical study will aid future formulation development and optimisation of AZD9668 tablets by evaluating possible effects of minor changes to the formulation and process on the rate and extent of absorption.

Timeline

Start
2009-11
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alvelestat Small molecule 60 mg Oral